• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: A dual vector gene therapy product containing AAV8 vectors expressing the 5¿ and 3¿ portion of human otoferlin (OTOF) gene
Date Designated: 11/29/2022
Orphan Designation: Treatment of otoferlin related hearing loss
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Sensorion S.A.
375 rue du Professeur Joseph Blayac
Montpellier 34080
France

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-